ReAble, DJO merger gets FTC (Federal Trade Commission) go-ahead:
This article was originally published in Clinica
ReAble Therapeutics' merger with musculoskeletal and vascular health specialist DJO Incorporated has received the green light from the US Federal Trade Commission, after it granted early termination of the required antitrust waiting period. The deal, which will see private equity company The Blackstone Group acquire Vista, California-based DJO and merge it with ReAble (see Clinica No 1265, p 11), is expected to close in the fourth quarter of 2007, and is worth approximately $1.6bn.
You may also be interested in...
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.